Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

The Trump administration is exploring a five-year pilot program to include weight-loss drugs like Wegovy, Ozempic, Zepbound, ...

The Trump administration is preparing a five-year pilot program that could allow Medicare and Medicaid to cover expensive GLP-1 weight loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound. If ...

UnitedHealth Group's pharmacy benefits manager, OptumRx Inc., was hit with an Employee Retirement Income Security Act of 1974 ...

CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

Among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers ...

Novo's Wegovy and Eli Lilly's Zepbound are listed at $1,086 and $ ... Employers are also eyeing alternatives to traditional pharmacy benefit managers, according to Mercer. PBMs such as CVS Caremark, ...

GLP-1 drugs, a class of obesity and diabetes medications that includes Ozempic, Wegovy, Zepbound, and Mounjaro, are known to produce significant weight loss.